COMMUNIQUÉS West-GlobeNewswire

TECVAYLI®▼ (téclistamab) révèle son potentiel en tant que traitement combiné de première ligne destiné aux patients atteints d’un myélome multiple nouvellement diagnostiqué
11/12/2024
100 pour cent des patients chez qui la maladie résiduelle minimale (MRM) était évaluable ont atteint une MRM négative dans le cadre de l’étude MajesTEC-5 évaluant le produit en traitement d’induction, et dans le cadre [...]
RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates
11/12/2024
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS) announced that the United [...]
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
11/12/2024
Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment NASHUA, N.H., Dec. 11, 2024 (GLOBE [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
11/12/2024
Please see enclosed pdf. Attachment 11122024_trading_in_shares_GL
USOSM President and CEO Richard Hall Named to SCALE’s Most Influential Healthcare Leaders List
11/12/2024
IRVING, Texas, Dec. 11, 2024 (GLOBE NEWSWIRE) -- For the second year in a row, SCALE Healthcare has named U.S. Oral Surgery Management ( USOSM ) President and CEO Richard Hall to its list of Most Influential Healthcare [...]
NADP Report Reveals Overall Decrease in Dental Benefits Enrollment
11/12/2024
Some Market Growth Seen in Public and Private Segments DALLAS, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enrollment in dental benefits decreased last year to 87% of the U.S. population— a 1% decline from the previous year, [...]
Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease
11/12/2024
Grasse, France and Leiden, the Netherlands – 11 December 2024 – Phenocell SAS (part of Axol Bioscience ) a leading provider of stem cell-derived models and services, and Amarna Therapeutics , a biotechnology pioneer in [...]
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11/12/2024
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has approved commencing [...]
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
11/12/2024
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded [...]
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
11/12/2024
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, [...]
Gain Therapeutics To Present At Biotech Showcase 2025
11/12/2024
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical- [...]
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
11/12/2024
The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or [...]
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
11/12/2024
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry [...]
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
11/12/2024
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes [...]
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
11/12/2024
ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 [...]
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11/12/2024
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting [...]
Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)
11/12/2024
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs [...]
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
10/12/2024
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI)
10/12/2024
NEW YORK , 10 déc. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour [...]

Pages